CD19 and hematologic disorder: Over the past two decades, CAR T cell therapies have demonstrated remarkable success, particularly in hematologic malignancies like B cell lymphoma, leukemia and MM, with FDA-approved CAR T products targeting antigens such as CD19 and BCMA [304–313] (Tables 2 and 3).